Maxim Group reiterated their buy rating on shares of OncoSec Medical Inc (NASDAQ:ONCS) in a research note issued to investors on Friday morning. The brokerage currently has a $5.00 target price on the stock.
Separately, Ci Capital started coverage on shares of OncoSec Medical in a report on Wednesday, December 28th. They issued a buy rating on the stock. Five equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus price target of $5.50.
OncoSec Medical (NASDAQ:ONCS) traded up 3.9677% on Friday, hitting $1.2892. 61,283 shares of the stock were exchanged. The stock’s market cap is $25.44 million. OncoSec Medical has a 12 month low of $1.03 and a 12 month high of $3.49. The company has a 50-day moving average of $1.34 and a 200-day moving average of $1.50.
Your IP Address:
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/oncosec-medicals-oncs-buy-rating-reaffirmed-at-maxim-group/1709245.html
Receive News & Ratings for OncoSec Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.